Health & New Arrivals
Health Canada announced Tuesday that an improved Pfizer-BioNTech vaccine has been approved to protect against recent circulating variants of COVID-19.
Three vaccines approved for approval in Canada in fall 2024
CBC News · Posted: September 24, 2024 1:04 PM EDT | Last updated: 7 minutes ago
This August 2024 photo shows packaging for Pfizer’s COVID-19 vaccine for people 12 and older. Health Canada says the product has been approved for use in the fall immunization campaign. (Steven DeCruz/The Canadian Press/Associated Press)
Health Canada announced Tuesday that an improved Pfizer-BioNTech vaccine designed to protect against recent circulating variants of COVID-19 has been approved.
The Federal Vaccine and Treatment Portal lists the approval of the Komilnati product, saying it contains an updated formulation targeting Omicron’s KP.2 variant.
Last week, Health Canada approved another mRNA vaccine, Moderna Inc’s Spikevax, as well as Novavax Inc’s protein-based vaccine called Nuvaxovid.
WATCH | Addressing the long-term health effects of COVID-19:
Experts say the impact of COVID-19 will extend far beyond the initial onset
Early studies suggest a worrying proportion of patients who recover from COVID-19 are left with a chronic respiratory disease called pulmonary fibrosis.
Pfizer’s previous vaccine targeted an earlier Omicron variant called XBB.1.5.
The newer Pfizer and Moderna vaccines are approved for adults and children 6 months and older.
Novavax is approved for adults and people 12 years of age and older.
Corrections and Clarifications | Submit a News Tip | Report an Error
Source link
